18 May 2013
Keywords: Novartis, Vectura, Sosei, COPD, NVA237
Article | 01 July 2011
Swiss drug major Novartis (NOVN: VX) has announced positive results from the pivotal Phase III GLOW2 clinical trial showing that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 July 2011
30 June 2011
17 May 2013
© 2013 thepharmaletter.com